{"id":"cd30-car-ebvst-cells","_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"modality":"Biologic","_dailymed":null,"mechanism":{"target":"CD30","explanation":"These cells are Epstein-Barr virus-specific T cells engineered with a chimeric antigen receptor (CAR) directed against CD30, a surface protein expressed on certain lymphomas. The dual functionality allows targeting of CD30-positive tumors while maintaining anti-viral immunity against EBV.","oneSentence":"Genetically modified T cells that target CD30-expressing cancer cells while retaining activity against EBV-infected cells."},"_scrapedAt":"2026-03-28T05:57:31.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123261,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"brentuximab vedotin","brand":"Adcetris","company":"Seagen","rationale":"Approved antibody-drug conjugate targeting CD30-positive lymphomas"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"CAR T-cell therapy for relapsed/refractory large B-cell lymphoma"}],"description":"CD30.CAR-EBVST cells are an investigational cell therapy developed by Baylor College of Medicine. This approach combines CAR T-cell technology with Epstein-Barr virus-specific T cells targeting CD30-positive malignancies, currently in early-phase clinical development.","indications":{"approved":[{"status":"investigational","condition":"CD30-positive lymphomas","patientPopulation":"Relapsed or refractory"}]},"trialDetails":[{"nctId":"NCT06176690","phase":"PHASE1","title":"Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-10-27","conditions":"CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":90},{"nctId":"NCT04288726","phase":"PHASE1","title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-09-16","conditions":"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT04952584","phase":"PHASE1","title":"Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2024-03","conditions":"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4416852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes"],"phase":"phase_1","status":"active","brandName":"CD30.CAR-EBVST cells","genericName":"CD30.CAR-EBVST cells","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","firstApprovalDate":"","aiSummary":"CD30.CAR-EBVST cells are a type of immunotherapy used to treat CD30-positive lymphomas, including diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and peripheral T-cell lymphoma. They are a form of chimeric antigen receptor (CAR) T cells that are modified to recognize and target CD30-positive cancer cells.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}